Wire · opportunities
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
The European Commission approved the combination of teclistamab and daratumumab for adult patients with relapsed or refractory multiple myeloma after at least one prior therapy, based on the phase 3 MajesTEC-3 trial demonstrating significant improvement in progression-free and overall survival compared to standard treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 21 Aug 2026 and 24 Aug 2026.
◆ ◆ The Wire takeaway
Cancer therapy founders now face a defined regulatory pathway and earlier market access for immunotherapy combos in Europe. You need to position your clinical assets against teclistamab's success to avoid losing competitive edge.
◆ Coverage
2 sources · first reported 21 Aug 2026 · latest 24 Aug 2026
◆ Related on Wire
◆ Topics